Effect of peroxisome proliferator-activated receptor gamma ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  International Journal of Cardiology

• Publication date

  2006-10-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.IJCARD.2006.03.060PMID 16891009
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project.

  2005cited by this paper
• PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1.

  2005cited by this paper
• Effects of peroxisome proliferator-activated receptor γ activator rosiglitazone on myocardial ischemic-reperfusion injury in rats

  2005cited by this paper
• Pioglitazone improves left ventricular diastolic function in patients with essential hypertension.

  2005cited by this paper
• Inflammatory cytokines and postmyocardial infarction remodeling.

  2004cited by this paper
• Angiotensin II Regulation of Collagen Type I Expression in Cardiac Fibroblasts: Modulation by PPAR-&ggr; Ligand Pioglitazone

  2004cited by this paper
• Anoxia-Reoxygenation Stimulates Collagen Type-I and MMP-1 Expression in Cardiac Fibroblasts: Modulation by the PPAR-γ Ligand Pioglitazone

  2004cited by this paper
• Peroxisome proliferator activated‐receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction

  2004cited by this paper
• Peroxisome proliferation-activated receptor-gamma ligands ameliorate experimental autoimmune myocarditis.

  2003cited by this paper
• Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association

  2003cited by this paper
• Peroxisome Proliferator-Activated Receptor-&agr; and Receptor-&ggr; Activators Prevent Cardiac Fibrosis in Mineralocorticoid-Dependent Hypertension

  2003cited by this paper
• The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction.

  2003cited by this paper
• Pioglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, Attenuates Myocardial Ischemia/Reperfusion Injury in a Rat Model

  2003cited by this paper
• Peroxisome proliferation-activated receptor-γ ligands ameliorate experimental autoimmune myocarditis

  2003cited by this paper
• Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

  2003cited by this paper
• Peroxisome Proliferator-Activated Receptor γ Plays a Critical Role in Inhibition of Cardiac Hypertrophy In Vitro and In Vivo

  2002cited by this paper
• Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats.

  2002cited by this paper
• Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.

  2002cited by this paper
• Pioglitazone, a Peroxisome Proliferator-Activated Receptor-&ggr; Agonist, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction

  2002cited by this paper
• Troglitazone inhibits growth and improves insulin signaling by suppression of angiotensin II action in vascular smooth muscle cells from spontaneously hypertensive rats.

  2002cited by this paper
• Structure, Endothelial Function, Cell Growth, and Inflammation in Blood Vessels of Angiotensin II–Infused Rats: Role of Peroxisome Proliferator–Activated Receptor-&ggr;

  2002cited by this paper
• Troglitazone Improves Cardiac Function in Patients with Congestive Heart Failure

  2002cited by this paper
• Ca2+‐sensitizing effect is involved in the positive inotropic effect of troglitazone

  2001cited by this paper
• Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells.

  2001cited by this paper
• Troglitazone, an antidiabetic drug, improves left ventricular mass and diastolic function in normotensive diabetic patients.

  2001cited by this paper
• Peroxisome Proliferator-Activated Receptor &ggr; Activators Inhibit Cardiac Hypertrophy in Cardiac Myocytes

  2001cited by this paper
• In Vivo Myocardial Protection From Ischemia/Reperfusion Injury by the Peroxisome Proliferator–Activated Receptor-&ggr; Agonist Rosiglitazone

  2001cited by this paper
• Transcriptional Suppression of Type 1 Angiotensin II Receptor Gene Expression by Peroxisome Proliferator-Activated Receptor-γ in Vascular Smooth Muscle Cells.

  2001cited by this paper
• Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells.

  2000cited by this paper
• The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II.

  2000cited by this paper
• Peroxisome Proliferator-Activated Receptor γ Activators Downregulate Angiotensin II Type 1 Receptor in Vascular Smooth Muscle Cells

  2000cited by this paper
• Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts.

  1999cited by this paper
• Troglitazone inhibits angiotensin II‐induced extracellular signal‐regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells

  1999cited by this paper

• Expanding telmisartan’s therapeutic horizon: exploring its multifaceted mechanisms beyond cardiovascular disorders

  2024cites this paper
• No causal effects between rosiglitazone and cardiovascular disease or risk factors: a Mendelian randomization study.

  2023cites this paper
• Catalpol ameliorates doxorubicin-induced inflammation and oxidative stress in H9C2 cells through PPAR-γ activation

  2020cites this paper
• PPARs and Myocardial Infarction

  2020cites this paper
• Aggravation of Cerebral Ischemia/Reperfusion Injury by Peroxisome Proliferator-Activated Receptor-Gamma Deficiency via Endoplasmic Reticulum Stress

  2019cites this paper
• Sphingolipid Synthesis Inhibition by Myriocin Administration Enhances Lipid Consumption and Ameliorates Lipid Response to Myocardial Ischemia Reperfusion Injury

  2019cites this paper
• Ghrelin Ameliorates Angiotensin II-Induced Myocardial Fibrosis by Upregulating Peroxisome Proliferator-Activated Receptor Gamma in Young Male Rats

  2018cites this paper
• The impact of oral anti-diabetic medications on heart failure: lessons learned from preclinical studies

  2018cites this paper
• PPAR-γ is involved in the protective effect of 2,3,4',5-tetrahydroxystilbene-2-O-beta-D-glucoside against cardiac fibrosis in pressure-overloaded rats.

  2016cites this paper
• Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure?

  2016influential citation
• Role of Pleiotropic Properties of Peroxisome Proliferator-Activated Receptors in the Heart: Focus on the Nonmetabolic Effects in Cardiac Protection.

  2016cites this paper
• Disruption of calcium homeostasis by cardiac-specific over-expression of PPAR-γ in mice: A role in ventricular arrhythmia.

  2016cites this paper
• Cross Talk between Oxidative Stress, PPAR- γ and RAS System in Diabetic Rat Heart Exposed to Ischemia / Reperfusion Injury

  2014cites this paper
• Hesperidin Produces Cardioprotective Activity via PPAR-γ Pathway in Ischemic Heart Disease Model in Diabetic Rats

  2014cites this paper
• Hesperidin blunts streptozotocin-isoproternol induced myocardial toxicity in rats by altering of PPAR-γ receptor.

  2014cites this paper
• PPAR Gamma at the Crossroads of Health and Disease: A Masterchef in Metabolic Homeostasis

  2014cites this paper
• Pleiotropic effects of PPARγ agonist on hemostatic activation in type 2 diabetes mellitus.

  2013cites this paper
• PPAR-γ activation by rosiglitazone suppresses angiotensin II-mediated proliferation and phenotypictransition in cardiac fibroblasts via inhibition of activation of activator protein 1.

  2013cites this paper
• Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: a translational perspective for the cardiologist.

  2013cites this paper
• PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty

  2012cites this paper
• Biology and therapeutic applications of peroxisome proliferator- activated receptors.

  2012cites this paper
• Thematic Review Series: New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases PPAR- as a therapeutic target in cardiovascular disease: evidence and uncertainty

  2012cites this paper
• Rosiglitazone suppresses lipopolysaccharide-induced matrix metalloproteinase-2 activity in rat aortic endothelial cells via Ras-MEK1/2 signaling.

  2012cites this paper
• Telmisartan attenuates isoproterenol-induced cardiac remodeling in rats via regulation of cardiac adiponectin expression

  2011cites this paper
• Effect of rosiglitazone on cardiac electrophysiology, infarct size and mitochondrial function in ischaemia and reperfusion of swine and rat heart

  2011cites this paper
• Effects of Chronic Rosiglitazone Treatment on Renal Handling of Salt and Water in Rats With Volume-Overload Congestive Heart Failure

  2011cites this paper
• Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma

  2011cites this paper
• PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system?

  2011cites this paper
• Anti-inflammatory activity of telmisartan in rat models of experimentally-induced chronic inflammation: Comparative study with dexamethasone.

  2011cites this paper
• PPARs as therapeutic targets in cardiovascular disease

  2010cites this paper
• The inhibitory effects of rosiglitazone on cardiac hypertrophy through modulating the renin‐angiotensin system in diet‐induced hypercholesterolemic rats

  2010cites this paper
• Rosiglitazone reverses cardiac adverse remodeling (fibrosis and vascularization) in perinatal low protein rat offspring.

  2010cites this paper
• Activation of PPARγ by pioglitazone does not attenuate left ventricular hypertrophy following aortic banding in rats

  2010cites this paper
• Modulation of PPAR-gamma by telmisartan protects the heart against myocardial infarction in experimental diabetes.

  2010cites this paper
• PPARs as therapeutic targets in cardiovascular disease

  2010cites this paper
• Thiazolidinediones and Congestive Heart Failure: A Judicious Balance of Risks and Benefits

  2009cites this paper
• Myocardial salvaging effect of telmisartan in experimental model of myocardial infarction.

  2009cites this paper
• Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease.

  2009cites this paper
• Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice

  2009cites this paper
• Agonists at PPAR‐γ suppress angiotensin II‐induced production of plasminogen activator inhibitor‐1 and extracellular matrix in rat cardiac fibroblasts

  2008cites this paper
• Peroxisome proliferator-activated receptor-gamma protects against hepatic ischemia/reperfusion injury in mice.

  2008cites this paper
• Metabolic Syndrome and Insulin Resistance: Perioperative Considerations

  2008cites this paper
• Peroxisome proliferator‐activated receptors and inflammation: take it to heart

  2007cites this paper
• PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance.

  2007cites this paper
• Peroxisome proliferator‐activated receptor‐γ protects against hepatic ischemia/reperfusion injury in mice

  2007cites this paper